Major medtech players presented a range of intriguing studies at a gathering of some of the biggest names in the cardiology tech space. Some of the hottest topics were covered this past week at the American College of Cardiology’s Annual Scientific Session Together With the World Congress of Cardiology (ACC.23/WCC) in New Orleans. Ablation, cardiac […]
ACC 2023
Biosense Webster marks first cases with dual energy ablation tech
Biosense Webster today announced the first cases with its investigational Thermocool SmartTouch SF dual energy catheter for treating AFib. The system enables doctors performing an ablation to toggle between two types of energy: pulsed-field and radiofrequency. It appears to be the Johnson & Johnson MedTech subsidiary’s answer to the dual energy ablation tech coming out […]
Real-world study backs iRhythm Zio XT
iRhythm Technologies (Nasdaq:IRTC) today announced findings supporting its Zio XT wearable heart monitoring technology. San Francisco-based iRhythm presented multiple new studies at the American College of Cardiology’s Annual Scientific Session Together With the World Congress of Cardiology (ACC.23/WCC). The Camelot study compared effectiveness of ambulatory monitors for arrhythmia diagnosis. It demonstrated that long-term continuous monitoring […]
Philips presents positive study results for its cardiology solutions
Philips (NYSE:PHG) today announced various clinical study results validating its innovations in cardiac and cardiovascular care. Amsterdam-based Philips presented its findings at ACC.23/WCC in New Orleans. Results included trends with intravascular imaging, early cardiac implant removal and intracardiac echocardiography catheters. “To make a real difference to patients, it is vitally important that medical innovations are […]
Edwards Lifesciences finds low re-intervention rates at 10 years for TAVR patients
Edwards Lifesciences (NYSE:EW) today announced data supporting transcatheter aortic valve replacement (TAVR) at 10 years. An analysis of Medicare data showed a low rate of re-intervention after TAVR out to 10 years. Dr. Suzanne Baron, a Boston-based interventional and structural cardiologist, led the analysis. Edwards presented results at the American College of Cardiology ACC.23/WCC. Of […]
Medtronic touts 3-year data for Evolut TAVR
Medtronic (NYSE:MDT) announced three-year data supporting its Evolut transcatheter aortic valve replacement (TAVR) system. Findings from the Evolut Low-Risk trial demonstrated numerically better clinical outcomes for the Evolut TAVR system. It also showed significantly better hemodynamic valve performance compared to surgical aortic valve replacement (SAVR). The study evaluated a low-risk aortic stenosis (AS) patient population. […]
Abbott reports positive study results for MitraClip, TriClip heart valve repair devices
Abbott (NYSE:ABT) announced late-breaking data supporting both its MitraClip and TriClip heart valve repair devices. Five-year data from the COAPT trial demonstrated the safety and efficacy of MitraClip for people with mitral regurgitation (MR). Data also showed the superiority of the TriClip transcatheter edge-to-edge repair (TEER) system. The Triluminate pivotal study evaluated TriClip against medical […]
Medtronic pulsed-field ablation system exceeds safety goal in study
Medtronic (NYSE:MDT) announced today that its PulseSelect pulsed-field ablation (PFA) system exceeded its safety performance goal in a clinical trial. PulseSelect registered an adverse event rate of 0.7%. Medtronic said that marks one of the lowest adverse event rates of any previous FDA investigational device exemption (IDE) trial for AFib ablation or any multi-center PFA […]
